앨나일람(ALNY) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 앨나일람(ALNY)?

앨나일람(ALNY) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of ALNY?

The market cap of ALNY is approximately $36.3B, ranking 405 within its sector.

Q: What is the P/E ratio of ALNY?

ALNY has a P/E ratio of approximately 64.6x, which can be used to assess its valuation relative to the Healthcare sector average.

Q: What is the 52-week high and low for ALNY?

ALNY has recorded a 52-week high of $495.55 and a low of $262.21.

ALNY

Alnylam Pharmaceuticals Inc

7월 27일 12:38 PM ET (한국 7/28 01:38)

$271.77

+3.03 ▲ +1.13%

앨나일람(ALNY) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$36.3B

미드캡

P/E

64.6

고평가 구간

배당수익률

없음

52주 위치

저점 +4% · 고점 -45%

애널리스트

매수

B+

Fundamental health

vs. Biotechnology 대형주

수익성

Top 33%

성장

Top 11%

밸류에이션

Top 27%

재무 안정

Top 30%

Index ⓘ	NDX	P/E ⓘ	64.57	EPS (ttm) ⓘ	4.21	Insider Own ⓘ	0.43%	Shs Outstand ⓘ	133.4M	Perf Week ⓘ	1.61%
Market Cap ⓘ	36.28B	Forward P/E ⓘ	25.29	EPS next Y ⓘ	44.13%	Insider Trans ⓘ	-9.58%	Shs Float ⓘ	132.9M	Perf Month ⓘ	-7.58%
Enterprise Value ⓘ	36.25B	PEG ⓘ	0.31	EPS next Q ⓘ	1.63	Inst Own ⓘ	98.93%	Short Float ⓘ	4.36%	Perf Quarter ⓘ	-13.39%
Income ⓘ	0.58B	P/S ⓘ	8.46	EPS this Y ⓘ	219.96%	Inst Trans ⓘ	1.36%	Short Ratio ⓘ	4.54	Perf Half Y ⓘ	-26.55%
Sales ⓘ	4.29B	P/B ⓘ	33.72	EPS next 5Y ⓘ	80.98%	ROA ⓘ	12.36%	Short Interest ⓘ	5.80M	Perf YTD ⓘ	-31.66%
Book/sh ⓘ	8.06	P/C ⓘ	12.06	EPS past 3/5Y ⓘ	-	ROE ⓘ	96.94%	52W High ⓘ	-45.16% ($495.55)	Perf Year ⓘ	-17.14%
Cash/sh ⓘ	22.54	P/FCF ⓘ	56.58	Sales past 3/5Y ⓘ	52.98% 49.77%	ROIC ⓘ	15.3%	52W Low ⓘ	3.65% ($262.21)	Perf 3Y ⓘ	41.31%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	44.92	EPS Y/Y TTM ⓘ	308.45%	Gross Margin ⓘ	80.83%	Volatility(W/M) ⓘ	3.89% 4.85%	Perf 5Y ⓘ	48.99%
Dividend TTM ⓘ	-	EV/Sales ⓘ	8.45	Sales Y/Y TTM ⓘ	82.57%	Oper. Margin ⓘ	17.54%	ATR (14) ⓘ	12.95	Perf 10Y ⓘ	314.98%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	3.06	EPS Q/Q ⓘ	440.32%	Profit Margin ⓘ	13.46%	RSI (14) ⓘ	39.31	Recom ⓘ	1.66
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	3.13	Sales Q/Q ⓘ	96.43%	SMA20 ⓘ	-6.62% ($291.04)	Beta ⓘ	0.29	Target Price ⓘ	$437.59
Payout ⓘ	-	Debt/Eq ⓘ	2.76	Earnings ⓘ	2026/7/30	SMA50 ⓘ	-6.89% ($291.88)	Rel Volume ⓘ	0.86	Prev Close ⓘ	$268.74
Employees ⓘ	2500	LT Debt/Eq ⓘ	2.51	EPS/Sales Surpr. ⓘ	73.26% 4.63%	SMA200 ⓘ	-23.32% ($354.42)	Avg Volume(3M) ⓘ	1.28M	Price ⓘ	$271.77
IPO ⓘ	2004/5/28	Option/Short ⓘ	Yes/Yes			Trades ⓘ	22370	Volume ⓘ	1,099,596	Change ⓘ	1.13%

Quarterly earnings trend SEC filings · USD

24.3

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

Revenue Net income 최근 분기: 매출 $1.1B (YoY +85%) · 순이익 $147M (YoY +276%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Alnylam Pharmaceuticals Inc (ALNY) Investment Analysis

What kind of company is Alnylam Pharmaceuticals Inc?

앨나일람(ALNY) 초고성장주

Healthcare · Biotechnology

Top 405 by Market Cap — Large-Cap

🧬 A leading biotech company in RNAi (RNA interference)-based drug development. Founded in 2002 in Cambridge, Massachusetts, the company is headquartered in the United States and operates an RNAi therapeutics pipeline targeting rare genetic disorders, cardiovascular, central nervous system, and liver diseases. It stands as a flagship company within a leading biotech group in the RNAi therapeutics space.

Learn more about Alnylam Pharmaceuticals Inc →

Market Cap

$36.3B

Approx. KRW 49.7 trillion

⚖️ 13% of Samsung Electronics

Market Cap Rank405

Employees2,500people

IPO2004/05/28

Current Price$271.77 ≈ 372,325원

📌 NDX · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-3

7월 30일 (목) · 장 시작 전

예상 EPS $1.63

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 4월 30일 (목) · 장 시작 전 EPS +73.3% 매출 +4.6%

🔔 Earnings release 2026년 2월 12일 (목) · 장 시작 전

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

17.5%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 14.7% · Top 44%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

13.5%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 8.6% · Top 44%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

80.8%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 86.4% · Bottom 36%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

96.9%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 11.9% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

12.4%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 대형주 Median 5.1% · Top 20%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

15.3%

✓ 우수

My positionTop 25%

Low range Average High range

Healthcare 대형주 Median 7.4% · Top 24%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

2.76

✓ Very high debt

My positionBottom 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

3.13

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.06

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$437.59

현재가 대비 +61.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

25.29배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

0.31

저평가

💡 PEG < 1 — 성장 대비 저렴

내년 EPS 예상 성장률

+44.1%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+81.0%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+9.4%

평균 서프라이즈

2026.04.30

상회

실적 $1.99 · 예상 $1.47 +35.3%

2026.02.12

하회

실적 $1.25 · 예상 $1.50 -16.5%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+220.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 47.1% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+44.1%

양호

My positionMid-range

Low range Average High range

초고성장주 대형주 Median 32.1% · Top 31%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+81.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 36.4% · Top tier

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+49.8%

우수

My positionTop 25%

Low range Average High range

초고성장주 대형주 Median 28.9% · Top 21%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+96.4%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 25.3% · Top 4%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 19%p over 5 years

ALNY +49.0% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-19.0%p

behind the market

vs Health Care (XLV)

+25.3%p

ahead of the sector average

1-year basis

vs S&P 500

-33.6%p

Significantly behind the market

vs Health Care (XLV)

-36.9%p

Significantly behind the sector average

Rank among peers

5-year return Upper-Mid (50%) Based on 24 peers

1-year return Lowest among peers Based on 24 peers

Current position within 52-week range

Low (-3.6%p) High (-45.2%p)

Current price is 3.6% above the 52-week low and 45.2% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-24.1%

Annualized volatility

36.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-24

Downtrend zone

Current price $271.77 below the midline ($291.04). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-24

Bearish momentum holding

MACD -7.476 < Signal -4.473 in negative zone + Hist negative (-3.004). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-24

Bearish zone

RSI 39.3 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 8.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Cheap on Vs. Sales, Pricey on Vs. Earnings·Vs. Assets·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Pricey

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

64.57x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology median 15.34x · Bottom 11% — expensive within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

25.29x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 22.38x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

33.72x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Biotechnology 대형주 median 7.26x · Bottom 4% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

8.46x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 9.45x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

44.92x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology median 22.58x · Bottom 25% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

56.58x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology median 18.43x · Bottom 24% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$437.59 vs. current price +61.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership flow is positive

Insider modest net selling -9.6% · Institutional net buying +1.4% · Short interest light 4.4% · Short interest up +0.9pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-9.6%

Insiders net selling

🏦 Institutions (funds & investors)

+1.4%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 98.9%

Institution-led, stable structure

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.4%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 0.6%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

4.4%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 90 days 📈 +0.9%p increase

Short interest days to cover

4.5 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 133.4M주

Float (tradable shares) 132.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ALNY

ETFs with the highest weightings · 10 total shown

PBE

Invesco Biotechnology & Genome ETF

4.84%

$283M

EGGY

NestYield Dynamic Income ETF

4.66%

$153M

EGGQ

NestYield Visionary ETF

4.62%

$85M

MEDX

Horizon Kinetics Medical ETF

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ALNY This Stock	$36.3B	64.6 ▼	33.7 ▼	96.94% ▲	-	+1.1%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

FAQ

What kind of company is 앨나일람(ALNY)?

앨나일람(ALNY) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ALNY?

The market cap of ALNY is approximately $36.3B, ranking 405 within its sector.

What is the P/E ratio of ALNY?

ALNY has a P/E ratio of approximately 64.6x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for ALNY?

ALNY has recorded a 52-week high of $495.55 and a low of $262.21.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.